Prospective Systematic Data Collection in Early COVID-19 Patients: A Protocol for Individualized Treatment and Outcomes Research

Author: Flávio Dantas

Corresponding author contact details: Prof. Flávio Dantas. MD
E-mail: dantasoliveirallavio@gmail.com
Affiliation: Department of Clinical Medicine, Federal University of Uberlândia, Brazil (retired professor)
ORCID: https://orcid.org/0000-0002-2756-2412

Conflict of interest: None

ABSTRACT

Human infection caused by the SARS-CoV-2 virus (COVID-19) is a new pandemic disease with devastating effects worldwide. There is no scientifically proved effective prophylaxis or treatment in the early phase of the disease. To prevent harm, in parallel with the running of randomized controlled trials, there is room for developing prospective systematic data collection studies correlating therapeutic measures with safety and effectiveness outcomes, on the assumption that a medical practice is effective if it produces more good than harm. The protocol aims to provide doctors with information on reduction of harm in early COVID-19 patients by different and individualized strategies for treating them, including comparison with no treatment strategies. Besides laboratory confirmation of COVID-19, the evaluation of the clinical status is done with an individualized symptom score for each patient, self-perception of overall severity of disease, clinical improvement ordinal scale developed for WHO clinical studies on COVID-19 and doctors’ global impression on clinical prognosis at the first consultation and evolution at the closing. It respects the autonomy and preferences of doctors and patients to decide the best options for treatment in uncertain situations and allows the gathering of useful information for future more rigorous clinical trials, trying to link science, ethics, and personal clinical experience. A case report form was developed that could easily be built in free software platforms as well as dedicated platforms. All data are anonymized and could be analyzed by descriptive and inferential statistics.

Keywords: COVID-19; Treatment outcome; Data Collection; Pharmaceutical Preparations; Outcome Assessment, Health Care

INTRODUCTION

"Medicine is a science of uncertainty and an art of probability" according to a famous quote by William Osler, considered for many the father of modern medicine and of bedside teaching. Medicine as a science tries to discover useful generalizations in order to apply its product for other similar people while as and art is guided by personalized care and human needs consideration.

The implications of this dissonance can be seen in the evaluation of pharmacologic treatments for humans. It has been characterized by a tension between the implementation of strategies based on biomedical models - emphasizing efficacy, statistical significance, internal validity and group analysis - and the use of strategies based on biopsychosocial (or humanistic) models that favor effectiveness, clinical relevance, external validity and the analysis of individual results. In one hand, medical researchers want to know the efficacy of the drug, which refers to the extent in which a specific intervention, procedure, regime or service produces a benefit under ideal conditions. On the other hand, effectiveness indicates the point in which they produce what is expected for a certain population when used under routine circumstances. It is usually accepted that efficacy is determined through randomized clinical trials, while effectiveness
requires a larger variety of strategies, including observational studies (cohorts, case-controls), and even randomized studies comparing different treatments in real operational settings where consultation is provided.4

Medicine and physicians face daily decisions that require maximum certainty in settings with permanent uncertainties. This uncertainty has immutable roots, the most important being the nature of Human Beings: at the same time every person is equal by law, similar to each other in various aspects although completely unique and different from all other people. Besides this, doctors as professionals have diverse background, values and experiences that could lead to different decisions for the same situation, given the rapid changes in knowledge and technology environment surrounding their practice. COVID-19 constitutes a good example of this changing patterns as new information is being incorporated over time in an ambience of growing politicization of technical decisions on health, to be guided by unbiased science and ethical standards.

Evidence-Based Medicine (EBM) considers study design a decisive factor for judging the scientific validity of conclusions. In therapeutics, randomized clinical trials (RCT) or systematic reviews of RCT were top choice until September 2000, when individualized randomized studies (n-of-1) were also included as top of the rank, in terms of validity. This was decided by the leaders of the EBM after a clear awareness that RCT, despite their strong internal validity, presents insufficient external validity or low generalization capacity for other patients that doesn’ t meet the stringent and highly selective inclusion and exclusion criteria in RCT, thus lacking applicability in many cases. Clinical applicability is an attribute considered more important by those who practice medicine and need to apply the knowledge to each particular patient. A year before, concerned about clinical outcomes that could modify the practice in primary care, and after analyzing 8,085 research papers in primary care published by 85 medical journals in 6 months, a group of MBE enthusiasts came to the conclusion that only 2.6% of the papers addressed Patient Oriented Evidence that Matters (POEMs), 50% of these being published by 10 medical journals.

RCT are sometimes unnecessary, inappropriate, impossible or inadequate. For COVID-19 it would not be reasonable and proportionate to require RCT to substantiate treatment decisions soon after its onset. The indiscriminate acceptance of RCT as a guideline for minimally acceptable conclusions in therapeutic efficacy has led institutions that are responsible for boosting medical research and medical journal editors to consider only this study category, denying the potential scientific value of rigorously conducted observational studies. In pandemics such as COVID-19, prospective systematic documentation of a cohort of patients and correlation of relevant clinical outcomes, obtained after the use (or not) of concurrent therapeutic procedures, could be a cheap and easier opportunity to get reliable data in order to decide which are the best candidates to RCT, in case they are still needed.

THE PROPOSAL

The prospective data collection and evaluation of significant clinical outcomes, after interventions prescribed by large number of doctors under normal circumstances, is a viable strategy to get good quality and large amount of information on the effects of different pharmacologic and non-pharmacologic interventions in suspected or confirmed patients of COVID-19. The proposal must be oriented towards the benefit of patients and the improvement of health care in a collective perspective, open to different and concurrent medically driven interventions and be assessed by rigorous and simple scales and clinimetric tools for measuring clinical outcomes.

The main assumptions of the proposal are:

i. Human Beings are at the same time similar to other and different from all other people

ii. A medical practice is effective if it produces more good than harm

iii. Physicians have the right to decide on the best treatment to patients under their responsibility and, in situations of high uncertainty, shouldn’t abdicate of their legitimate and legal right to take this decision. They should take decisions, after informed consent of their patients, according to their own values, knowledge and experience

iv. First try simple things to do less (or no) harm later

v. For patients, doing something under medical supervision is better than nothing, notably if what is being done is safe, simple, cheap and has clinical plausibility

vi. There is no better and exclusive study design to be accepted as evidence in highly uncertain and urgent situations such as COVID-19: observational and experimental studies could contribute, at their own pace and time, to better explain and take adequate clinical decisions exclusively in the best interests of patients.
Ethics

The protocol was designed to comply with ethical requirements needed for research in pandemics, as recommended by WHO and World Medical Association. An informed consent and authorization term for use of drugs not approved for COVID-19, as well as to the anonymized use of clinical information gathered from the personal care, should be obtained by doctors. It obeys WHO orientations for off-label drug prescription in patients with COVID-19 outside clinical trials, since there is no proven effective treatment and it will be well documented9. It is also aligned with the paragraph 37 of the Declaration of Helsinki which recommends that “the physician may use an unproven intervention if in his judgment it offers hope of saving life, restoring health or relieving suffering”, adding that this new information “must be recorded and, where appropriate, made publicly available”10. It is focused on the respect for the autonomy of doctors and patients, taking advantage of all potentially useful and available therapeutic procedures that could be effective for suspected or confirmed patients with early COVID-19 diagnosis.

Outcomes

The main outcomes will include: (1) change in total score of individualized COVID-19 symptoms; (2) Clinical improvement assessed by WHO clinical progression scale for COVID-1911 and patient’s self-perception overall severity of disease; (3) Number and seriousness of adverse effects; (4) Proportion of hospitalized patients, particularly for those considered to be at high risk in the first consultation; (5) time to symptoms resolution and return to regular activities after adoption (or not) of medical interventions and (6) Initial favorable response time of the organism after starting the treatment.

Clinical protocol elements

Each clinical protocol shall be structured taking into account the following criteria: simplicity, feasibility and methodological quality. It may contain a minimum number of mandatory elements, and others could be added according to local conditions and viability. The following chart summarizes the aforementioned elements as well as an example of the suggested scales for COVID-19 assessment:
Admission of patients
- Clinical and epidemiologic information with laboratory confirmed COVID-19 (RT-PCR) - Onset of symptoms

Recording of clinical information
- Comorbidities - Degree of severity for each symptom - Use of other medicines for treating previous health problems

Treatment
- Description of all medicines in use as well as non-pharmacologic interventions - Dosage regimen - Minimum period of time for patient follow-up

Evaluation of therapeutic outcomes
- Measurement of clinical progression - Changes in Individualized symptom score - Description of adverse effects and complications

Example of assessment scales

Individualized Symptom Score for early COVID-19 patients

CURRENT SIGNS AND SYMPTOMS: Identify, in the box next to each symptom, its intensity in the patient using 0 if it is absent, 1 if it is mild, 2 if it is moderate and 3 if it is severe, calculating the score at the end.

| A (general) | Grade | B (local) | Grade | C (local and other) | Grade |
|-------------|-------|-----------|-------|---------------------|-------|
| □ Fatigue   | □ Headache | □ Nausea or Vomiting |
| □ Fever    | □ Conjunctivitis | □ Abdominal pain |
| □ Myalgia  | □ Rhinorrhea | □ Diarrhoea |
| □ Chill    | □ Sore throat | □ Other (specify) |
| □ Ageusia  | □ Cough |
| □ Anosmia  | □ Dyspnoea |

TOTAL SCORE (A+B+C) =

WHO clinical progression scale

| Patient state          | Descriptor |
|------------------------|------------|
| Uninfected             | No viral RNA detected |
| Ambulatory mild disease| Asymptomatic, viral RNA detected |
| Ambulatory mild disease| Symptomatic, independent |
| Ambulatory mild disease| Symptomatic, needs assistance |
| Hospitalized moderate disease | No oxygen therapy |
| Hospitalized severe disease | Oxygen by mask or nasal prongs |
| Hospitalized severe disease | Non-invasive ventilation or high-flow oxygen |
| Hospitalized severe disease | Intubation and mechanical ventilation, pO2/FiO2 _150 or SpO2/FiO2 _200 |
| Hospitalized severe disease | Mechanical ventilation pO2/FiO2 <150 (SpO2/FiO2 <200) or vasopressors |
| Hospitalized severe disease | Mechanical ventilation pO2/FiO2 <150 and vasopressors, dialysis, or ECMO |
| Dead                   | Dead |

ECMO=extracorporeal membrane oxygenation. FiO2=fraction of inspired oxygen. NIV=non-invasive ventilation. pO2=partial pressure of oxygen. SpO2=oxygen saturation. *If hospitalised for isolation only, record status as for ambulatory patient.

Self-Perception Scale on overall severity of disease

Globally, how does THE PATIENT says how ill AT THIS MOMENT (s)he is?

| Extremely ill | A little ill |
|---------------|-------------|
| Seriously ill | A little bit ill, almost cured |
| Very ill      | Disease-free, cured |
| Moderately ill|             |
Analysis of data

Observational studies may be approached from an exploratory data analysis perspective. Data description strategies should be performed comprehensively, through graphs and charts, or applying influence analysis or sensitivity analysis, according to Greenland’s recommendations. Data gathering will inform most used pharmacological or non-pharmacological interventions, their associated (or not) use, dosage regimen, adverse effects and clinical complications. From an exploratory perspective (hypotheses generation), preliminary associations between main outcomes for each package of medical interventions would be useful to search for most effective treatment strategies as well as to identifying possible adverse effects related to it. Other information such as presence of specific comorbidities, age or sex could be correlated with outcomes to propose clinical prognostic scales, as well as the occurrence of eventual side effects derived from the interaction of concomitant use of other medicines with COVID-19 interventions.

DISCUSSION

Science is a social, cumulative, and complex activity, to be done with maximal transparency and strict honesty. Respect for Human Beings is the only absolute principle of moral life, to be daily exercised by physicians in clinical practice and research. In a JAMA editorial commenting a publication of a halted clinical trial done in Brazil in which a group of critically ill COVID-19 patients used an extravagant 20g of chloroquine diphosphate for 10 consecutive days, it was stated that “science poorly conducted or poorly reported is counter to the public interest”. No one would disagree with this, although a nuclear and common attribute to both medical science and medical art is ethics, and in particular the virtue of prudence. Ars Medica (AM) can be expressed in the equation AM = E [EBM+ (E, BM)]² where E is Ethics and Eₓ BM is Experience Based Medicine. Without Ethics there is no good medicine or even medicine at all.

COVID-19 is a disease with wide clinical presentation and uncertain prognosis where there is no efficacious treatment or preventive measures. To treat any viral disease, physicians should consider two general strategies: to increase the defense power of the organism and to inhibit the aggression power of the virus, mainly by stopping or reducing its replication. It appears that only the last is being object of focus in COVID-19 pandemics with a search for effective pharmacological interventions. With the same intention of doing not more harm than good, some doctors and health authorities advocate that, in the early stage, no treatment is often the best treatment and patients should stay quiet at home until the development of more severe symptoms, albeit others argue on the importance of empirical treatment and close observation of its outcomes in order to prevent later ‘cytokine storm’ and the need of hospitalization and admission to intensive care units. Given the short time since the pandemics started, both sides don’t have sufficient and robust empirical or experimental findings to support their beliefs or opinions.

However, even if the drugs prescribed as off label in the early phase of COVID-19 are later proved in RCT to have no specific effects against SARS-CoV-2 virus, the prescriber could argue that it was used after informed consent of patients and documentation of its outcomes, incorporating the contribution of context effects from the doctor-patient relationship which could be linked to better therapeutic effects. In fact, when explaining the reasons for prescribing the medicine and getting the consent of patients for use of the medicine (and of his data for documentation), physicians could also explore preferences of patients and discuss non-pharmacologic treatments. A recent systematic review concluded that there are convincing effects on objective and subjective health outcomes from doctor-patient communication in clinical practice. On the other side, if these drugs show later to be effective in rigorous studies, it could be argued in judicial courts, against health authorities or physicians that prohibited or didn’t made available the drugs, the right to obtain damages for a heightened risk of death or injury. Medicine is not mathematics, patients are not numbers and emotions must count in order to restoring health to patients or alleviating their suffering.

By stimulating the use of all procedures that could help patients in observational studies, such as doctors’ communication and use of empathy with patients for deciding on the best intervention as well as specific educational recommendations (e.g. smoking cessation) and non-pharmacological procedures (such as regular gargling and nasal irrigation to prevent more harm), there is an addition of non-specific placebo effects which could lead to better therapeutic results. This kind of medical attitude is not usually adopted in RCT for drugs since the main objective is to observe if the drug alone could explain for the results and to reduce as much as possible all possible factors that could affect the outcomes. Only 5 papers in PubMed addressed the role of gargling and nasal irrigation in helping to combat coronavirus invasion in the early phase of COVID-19. It could be an important procedure since nasopharynx or oropharynx are the locus of
installation and replication of the virus, and a recent study showed that gargling/nasal irrigation with a hypertonic saline solution made at home reduced in 2 ½ days the duration of coronavirus common cold\textsuperscript{19,20}. This simple and cheap procedure, done early, could possibly help to reduce the viral load in patients, thus reducing the burden of disease and also its transmissibility rate.

The proposed protocol has several utilities and can be easily modified or adapted by any doctor or health manager interested in using it, especially for public health purpose. As a data collection of a prospective observational cohort, it could be useful to the early assessment of COVID-19 severity by correlating age of the patient, vital signs (e.g. fever), symptoms, comorbidities and other health indicators with later outcomes, including hospitalization and death. It could also be useful to compare patients who don’t want to use antiviral drugs but only gargling and nasal irrigation while others could use pharmacological interventions (e.g. chloroquine phosphate/hydroxychloroquine, azithromycin, zinc sulphate, ivermectin, nitazoxanide, homeopathic medicines, herbal medicines, Traditional Chinese Medicine) associated or not to non-pharmacological interventions. A more sophisticated prognostic scale using weighted criteria could be developed along the follow-up, helping to more accurately predict the risk of severe COVID-19 from the early phase\textsuperscript{21}. A full version of the proposal, with the case report form and informed consent declaration, is available at https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1102394. The electronic google form in English could be accessed at https://forms.gle/B7CFd3Nm4oywk9T49 and in Portuguese it is available at https://forms.gle/Wu9rRJBoh9ZZ22iQA.

It has also some drawbacks related to the compliance of doctors to fulfil the CRF or the electronic form, and in the admission and follow up of all sequentially included patients to reduce bias. It is time consuming, particularly in a pandemic where time is a critical resource for doctors and health professionals. It cannot lead to the conclusion of efficacy for a given procedure, only to the effectiveness of the whole set of adopted procedures. It could be that despite the global effectiveness of the package, a particular drug on it could be a mere placebo. According to Shapiro, “the history of medical treatments is characterized by the introduction of new placebos by successive generations of physicians, often accompanied by vehement and vituperative denunciation of opposing physicians who prefer other placebos”. And conclude that “the strong beliefs of physicians, objectively unjustified, suggest that they have been as defensive about their treatments throughout medical history as they are today”, mentioning in the sequence some studies that “demonstrate that physicians attribute the use of placebos to other physicians three times as often as they attribute it to themselves”\textsuperscript{22}.

Patients would be pleased if they are assisted by good doctors in which they trust, and doctors are responsible for the prescription (or not) of a safe and possibly effective medicine to help patients. The prescription (or not) of medicines in early COVID-19 is a medical decision and must be done, given the uncertainty and the need to do more good than harm, without any kind of discrimination.

There is a political and unhealthy debate in Brazil and in other countries on the early use of repurposed drugs in COVID-19 among doctors and health scientists. There is no strong evidence to support the early use of drugs or only staying at home in the initial phase of viral replication. Patients are educated by medical industry and doctors to take some drug when they feel sick, and there is some pressure on this. When taking medical decisions, autonomy and preferences of both patients and doctors must be respected. Osler, in his 1905 farewell address to American doctors, preached union between homoeopaths and allopaths by saying “long past the time when a difference of belief in the action of drugs—the most uncertain element in our art!—should be allowed to separate men with the same noble traditions, the same hopes, the same aims and ambitions”\textsuperscript{23}. Perhaps this is the right time to practice tolerance, honesty, equanimity and prudence in conducting observational studies and gathering useful data, guided by doctors and public health authorities, to take better informed and less harmful clinical decisions to benefit COVID-19 patients and society as a whole in the early stage of the disease, helping them to quickly restore or protect their health.

Acknowledgements

The author thanks Eneas Faleiros MD for helpful comments on the original protocol and for encouraging the writing of the paper.

REFERENCES

1 Dantas F. Avaliação de resultados terapêuticos da homeopatia: uma proposta para a realidade brasileira. Rev Homeop. 2003; 68(1-2):47-62.
2 Diamond GA, Denton TA. Alternative Perspectives on the Biased Foundations of Medical Technology Assessment. Ann Intern Med 1993;118:455-64.
3 Last JM (ed). A dictionary of epidemiology. 3.ed. New York: Oxford University Press, 1995. p. 52.
4 Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using “real world” randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995; 48: 363-373. 
5 Guyatt GH et al. For the Evidence-Based Medicine Group. Users’ Guides to the Medical Literature. XXV: Evidence-Based Medicine: Principles for Reading and Using the Results of Research Studies of Treatment (Randomized Trials). JAMA 2000; 284: 1290-6. 
6 Ebell MH, Barry HC, Slawson DC, Shaughnessy AF. Finding POEMs in the medical literature. J Fam Pract. 1999; 48(5):350-5.
7 Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312:1215-8.
8 Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations: a report by the Canadian Task Force on the periodic health examination. J Clin Epid 1990; 43:891-905.
9 World Health Organization. Off-label use of medicines for COVID-19: Scientific brief. Available in: https://www.who.int/news-room/commentaries/detail/off-label-use-of-medicines-for-covid-19. Accessed 04/09/2020.
10 World Medical Association. Declaration of Helsinki of the World Medical Association: Ethical Principles for Medical Research involving Human Beings.
11 WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research [published online ahead of print, 2020 Jun 12]. Lancet Infect Dis. 2020; S1473-3099(20)30483-7. doi:10.1016/S1473-3099(20)30483-7
12 Tukey JW. Exploratory data analysis. Reading, MA: Addison-Wesley 1977
13 Rosenbaum PR. Discussing hidden bias in observational studies. Ann Intern Med 1991; 115: 901-5. 
14 Greenland S. Randomization, Statistics, and Causal Inference. Epidemiology 1990; 1:421-29. 
15 Fihn SD, Perencevich E, Bradley SM. Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019. Editorial. JAMA Netw Open. 2020;3(4): e209035. doi:10.1001/jamanetworkopen.2020.9035. Published online April 24, 2020. Available in https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765500
16 Porto CC, Dantas F. AC=E [MBE + (MBV)^2] : Uma equação matemática para a arte clínica de curar. Revista da Sociedade Brasileira de Clínica Médica 2003; 1(2):33-34.
17 Schenker Y, Fernandez A, Lo B. Placebo prescriptions are missed opportunities for doctor-patient communication. Am J Bioeth. 2009;9(12):48-50. doi:10.1080/15265160903234144
18 Riedl D, Schüßler G. The Influence of Doctor-Patient Communication on Health Outcomes: A Systematic Review. Z Psychosom Med Psychother. 2017;63(2):131-150. doi:10.13109/zptm.2017.63.2.131
19 Ramalingam S, Graham C, Dove J, Morrice L, Sheikh A. Hypertonic Saline Nasal Irrigation and Gargling Should Be Considered as a Treatment Option for COVID-19. J Glob Health 2020 Jun;10(1):010332. doi: 10.7189/jogh.10.010332
20 Ramalingam S, Graham C, Dove J, Morrice L, Sheikh A. A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold. Scientific Reports 2019; 9:1015. https://doi.org/10.1038/s41598-018-37703-3
21 Zhou Y, He Y, Yang H, Yu H, Wang T, Chen Z et al. Development and validation a nomogram for predicting the risk of severe COVID-19: A multi-center study in Sichuan, China. PLoS One. 2020;15(5): e0233328. Published 2020 May 18. doi:10.1371/journal.pone.0233328
22 Shapiro AK, Shapiro E. The powerful placebo: from ancient priest to modern physician. Baltimore: John Hopkins University Press, 1997. p.59
23 Osler W. Aequanimitas, 3rd ed. New York: Blakiston, 1953.